相关实验视频

Updated: May 10, 2025

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

阿斯丁可以通过多巴胺调节和脑肠轴调节缓解自发高血压大鼠的ADHD症状

Yueyang Leng^1,2,3, Ning Wu^1,2,3, Jing Wang^1,2,3

¹CAS and Shandong Province Key Laboratory of Experimental Marine Biology, Center for Ocean Mega-Science, Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, China.

Molecules (Basel, Switzerland)

|April 26, 2025

概括

阿斯塔桑丁 (ASTA) 通过改善神经递质水平和大脑肠轴健康来减轻注意力缺陷多动性障碍 (ADHD) 症状具有前景. 这种天然抗氧化剂具有作为儿科多动症辅助疗法的潜力.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
营养保健品营养保健品

背景情况:

注意缺陷多动性障碍 (ADHD) 是一种常见的神经发育障碍.
氧化压力与ADHD的发病有关.
作为一种强大的抗氧化剂,阿斯塔克桑丁 (ASTA) 正在探索其治疗潜力.

研究的目的:

研究阿斯塔克桑丁 (ASTA) 对ADHD症状和潜在机制的治疗作用.
评估ASTA对ADHD大鼠模型中神经递质系统,神经营养因子和脑肠轴的影响.

主要方法:

自发高血压大鼠 (SHRs),一个ADHD模型,被治疗ASTA (50/100毫克/公斤/天) 或atomoxetine (阳性对照).
行为测试 (开放场,莫里斯水迷宫) 评估过度活动,焦虑和空间记忆.
生物化学和组织学分析检查了神经营养因素,神经递质系统和脑肠相互作用.

主要成果:

在SHR大鼠中,ASTA治疗显著减轻了多动,焦虑和空间记忆缺陷.
改善与通过调节DR1,DAT,TH,SNAP-25和SERT恢复的多巴胺 (DA) 和血清激素水平有关.
ASTA还积极影响了结质细胞衍生神经变因子 (GDNF),保护小脑细胞,并调节了肠道微生物群.

结论:

在临床前模型中,阿斯塔丁在ADHD症状中显示出显著的治疗潜力.
ASTA通过调节多巴胺基系统,神经递质,神经营养因子和神经肠道环境而起作用.
阿斯塔是一种有前途的营养药物候选者,用于儿科多动症的辅助治疗.

关键词:

这是一种阿斯塔克桑丁 (astaxanthin).亚托莫克西丁 (atomoxetine) 是一种药物.注意缺陷多动障碍 (ADHD) 是一种注意缺陷多动障碍.多巴胺 (DA) 是一种我们的肠道微生物群.神经保护神经保护

更多相关视频

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Published on: January 7, 2019

相关概念视频

Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...

Drugs Acting on Autonomic Ganglia: Stimulants

Drugs Acting on Autonomic Ganglia: Stimulants

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...